Spark Therapeutics expects to begin patient dosing next year in a pivotal study for its next gene therapy candidate.
The experimental gene therapy is being developed as a treatment for hemophilia A.
Spark Therapeutics expects to begin patient dosing next year in a pivotal study for its next gene therapy candidate.
The experimental gene therapy is being developed as a treatment for hemophilia A.